Cargando…

Impact of pretreatment second look (18)FDG-PET/CT on stage and treatment changes in head and neck cancer

BACKGROUND: Patients diagnosed with locoregionally advanced head and neck squamous cell carcinoma (LAHNSCC) regularly undergo staging with (18)F-FDG PET/CT in our center. In cases of delays in radiotherapy (RT) planning CT more than 4 weeks after initial PET/CT or clinically suspected progress, PET/...

Descripción completa

Detalles Bibliográficos
Autores principales: Elicin, Olgun, Vollnberg, Bernd, Shelan, Mohamed, Riggenbach, Elena, Bojaxhiu, Beat, Mathier, Etienne, Giger, Roland, Aebersold, Daniel M., Klaeser, Bernd
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8414040/
https://www.ncbi.nlm.nih.gov/pubmed/34504959
http://dx.doi.org/10.1016/j.ctro.2021.08.007
_version_ 1783747748888051712
author Elicin, Olgun
Vollnberg, Bernd
Shelan, Mohamed
Riggenbach, Elena
Bojaxhiu, Beat
Mathier, Etienne
Giger, Roland
Aebersold, Daniel M.
Klaeser, Bernd
author_facet Elicin, Olgun
Vollnberg, Bernd
Shelan, Mohamed
Riggenbach, Elena
Bojaxhiu, Beat
Mathier, Etienne
Giger, Roland
Aebersold, Daniel M.
Klaeser, Bernd
author_sort Elicin, Olgun
collection PubMed
description BACKGROUND: Patients diagnosed with locoregionally advanced head and neck squamous cell carcinoma (LAHNSCC) regularly undergo staging with (18)F-FDG PET/CT in our center. In cases of delays in radiotherapy (RT) planning CT more than 4 weeks after initial PET/CT or clinically suspected progress, PET/CT is repeated for restaging and as an RT planning reference. Our aim was to determine the impact of second-look PET/CT on stage migration, treatment change and RT planning. METHODS: Consequent treatment changes were categorized as minor and major. Minor changes were defined as PET/CT-based modifications of RT plans, e.g., the addition of anatomical compartments, changes in high- and low-risk dose levels or both. Major changes included changes from curative to palliative treatment intent and alterations of interdisciplinary treatment plans, such as the addition of induction chemotherapy, switch to primary surgery, no treatment and/or the necessity of additional diagnostic work-up resulting in the postponement or cancellation of treatment. RESULTS: Thirty-two newly diagnosed LAHNSCC patients who were treated between 2014 and 2018 underwent second-look PET/CT (median interval 42.5 days). Second-look PET/CT led to locoregional and distant upstaging in 3/32 and 1/32 patients, respectively. In 1/32 patients (3%), second-look PET/CT led to a palliative approach with systemic treatment. New lymph node metastases were discovered in 16 patients, 6 of whom also showed significant progression of the primary tumor, resulting in minor changes in 16 of the remaining 31 patients (52%) who were treated curatively. CONCLUSION: If RT treatment planning of LAHNSCC was delayed by more than 4 weeks after initial PET/CT staging or when progression was clinically suspected, a second look at (18)FDG-PET/CT was performed. This led to changes in treatment planning in more than half of the cases, which is expected to directly influence oncologic outcomes.
format Online
Article
Text
id pubmed-8414040
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-84140402021-09-08 Impact of pretreatment second look (18)FDG-PET/CT on stage and treatment changes in head and neck cancer Elicin, Olgun Vollnberg, Bernd Shelan, Mohamed Riggenbach, Elena Bojaxhiu, Beat Mathier, Etienne Giger, Roland Aebersold, Daniel M. Klaeser, Bernd Clin Transl Radiat Oncol Article BACKGROUND: Patients diagnosed with locoregionally advanced head and neck squamous cell carcinoma (LAHNSCC) regularly undergo staging with (18)F-FDG PET/CT in our center. In cases of delays in radiotherapy (RT) planning CT more than 4 weeks after initial PET/CT or clinically suspected progress, PET/CT is repeated for restaging and as an RT planning reference. Our aim was to determine the impact of second-look PET/CT on stage migration, treatment change and RT planning. METHODS: Consequent treatment changes were categorized as minor and major. Minor changes were defined as PET/CT-based modifications of RT plans, e.g., the addition of anatomical compartments, changes in high- and low-risk dose levels or both. Major changes included changes from curative to palliative treatment intent and alterations of interdisciplinary treatment plans, such as the addition of induction chemotherapy, switch to primary surgery, no treatment and/or the necessity of additional diagnostic work-up resulting in the postponement or cancellation of treatment. RESULTS: Thirty-two newly diagnosed LAHNSCC patients who were treated between 2014 and 2018 underwent second-look PET/CT (median interval 42.5 days). Second-look PET/CT led to locoregional and distant upstaging in 3/32 and 1/32 patients, respectively. In 1/32 patients (3%), second-look PET/CT led to a palliative approach with systemic treatment. New lymph node metastases were discovered in 16 patients, 6 of whom also showed significant progression of the primary tumor, resulting in minor changes in 16 of the remaining 31 patients (52%) who were treated curatively. CONCLUSION: If RT treatment planning of LAHNSCC was delayed by more than 4 weeks after initial PET/CT staging or when progression was clinically suspected, a second look at (18)FDG-PET/CT was performed. This led to changes in treatment planning in more than half of the cases, which is expected to directly influence oncologic outcomes. Elsevier 2021-08-29 /pmc/articles/PMC8414040/ /pubmed/34504959 http://dx.doi.org/10.1016/j.ctro.2021.08.007 Text en © 2021 The Author(s) https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Article
Elicin, Olgun
Vollnberg, Bernd
Shelan, Mohamed
Riggenbach, Elena
Bojaxhiu, Beat
Mathier, Etienne
Giger, Roland
Aebersold, Daniel M.
Klaeser, Bernd
Impact of pretreatment second look (18)FDG-PET/CT on stage and treatment changes in head and neck cancer
title Impact of pretreatment second look (18)FDG-PET/CT on stage and treatment changes in head and neck cancer
title_full Impact of pretreatment second look (18)FDG-PET/CT on stage and treatment changes in head and neck cancer
title_fullStr Impact of pretreatment second look (18)FDG-PET/CT on stage and treatment changes in head and neck cancer
title_full_unstemmed Impact of pretreatment second look (18)FDG-PET/CT on stage and treatment changes in head and neck cancer
title_short Impact of pretreatment second look (18)FDG-PET/CT on stage and treatment changes in head and neck cancer
title_sort impact of pretreatment second look (18)fdg-pet/ct on stage and treatment changes in head and neck cancer
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8414040/
https://www.ncbi.nlm.nih.gov/pubmed/34504959
http://dx.doi.org/10.1016/j.ctro.2021.08.007
work_keys_str_mv AT elicinolgun impactofpretreatmentsecondlook18fdgpetctonstageandtreatmentchangesinheadandneckcancer
AT vollnbergbernd impactofpretreatmentsecondlook18fdgpetctonstageandtreatmentchangesinheadandneckcancer
AT shelanmohamed impactofpretreatmentsecondlook18fdgpetctonstageandtreatmentchangesinheadandneckcancer
AT riggenbachelena impactofpretreatmentsecondlook18fdgpetctonstageandtreatmentchangesinheadandneckcancer
AT bojaxhiubeat impactofpretreatmentsecondlook18fdgpetctonstageandtreatmentchangesinheadandneckcancer
AT mathieretienne impactofpretreatmentsecondlook18fdgpetctonstageandtreatmentchangesinheadandneckcancer
AT gigerroland impactofpretreatmentsecondlook18fdgpetctonstageandtreatmentchangesinheadandneckcancer
AT aebersolddanielm impactofpretreatmentsecondlook18fdgpetctonstageandtreatmentchangesinheadandneckcancer
AT klaeserbernd impactofpretreatmentsecondlook18fdgpetctonstageandtreatmentchangesinheadandneckcancer